Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)

Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8.

Authors

Amandeep Salhotra¹, Ahmed Aribi¹, Dat Ngo², Jianying Zhang³, Karamjeet Sandhu¹, Monzr Al-Malki¹, Haris Ali¹, Paul Koller¹, Shukaib Arslan¹, Elizabeth Budde¹, Samer Khaled¹, Sanjeet Dadwal⁴, David S Snyder¹, Andrew Artz¹, Stephen Forman¹, Ryotaro Nakamura¹, Anthony Stein¹, Guido Marcucci¹, Ibrahim Aldoss¹, Vinod Pullarkat¹

Affiliations

¹ Department of Hematology and HCT, City of Hope National Medical Center, Duarte, California.
² Department of Clinical Pharmacology, City of Hope National Medical Center, Duarte, California.
³ Department of Information Sciences, City of Hope National Medical Center, Duarte, California.
⁴ Division of Infectious Disease, City of Hope National Medical Center, Duarte, California.

PMID: 33719090
DOI: 10.1002/ajh.26157

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Combined Modality Therapy
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Female
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy
Liposomes
Male
Middle Aged
Neoplasms, Second Primary / drug therapy*
Neoplasms, Second Primary / mortality
Neoplasms, Second Primary / therapy
Remission Induction
Retrospective Studies
Sulfonamides / administration & dosage
Treatment Outcome

Substances

Bridged Bicyclo Compounds, Heterocyclic
CPX-351
Liposomes
Sulfonamides
Cytarabine
venetoclax
Daunorubicin